AgomAb Therapeutics NV (AGMB) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $253.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | EDIT |
|---|---|---|
| Share price | $5.45 | $1.64 |
| Market cap | $268.40M | $253.12M |
| 1-day change | -3.02% | -4.09% |
| YTD return | — | -20.00% |
| 1-year return | — | -32.23% |
| 5-year return | — | -94.93% |
| EPS (TTM) | $-2.08 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $40.52M |
| Revenue growth (YoY) | — | +25.39% |
| Net income (latest FY) | — | $-160.06M |
| Operating margin | — | -394.89% |
| Net margin | — | -395.01% |
| 52-week high | $17.82 | $3.94 |
| 52-week low | $5.39 | $1.63 |
| Distance from 52-week high | -69.42% | -58.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +591.19% | +271.95% |
| Average volume | 208.99K | 2.63M |
| Shares outstanding | 49.25M | 154.34M |
| Employees | 62 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
AGMB vs EDIT FAQ
Which is bigger, AgomAb Therapeutics NV or Editas Medicine?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $253.12M for Editas Medicine (EDIT).
Are AgomAb Therapeutics NV and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.